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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to 
FRUIT UP
®
 and a reduction of post-prandial blood glucose responses 
pursuant to Article 13(5) of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2,3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from WILD-Valencia SAU, submitted for authorisation of a health claim pursuant to 
Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Spain, the EFSA Panel on 
Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation 
of a health claim related to FRUIT UP
®
 and a reduction of post-prandial blood glucose responses. The Panel 
considers that the food, FRUIT UP
®
, and the food (i.e. glucose, sucrose) that FRUIT UP
®
 should replace in 
foods or beverages are both sufficiently characterised in relation to the claimed effect. A reduction of post-
prandial glycaemic responses (as long as post-prandial insulinaemic responses are not disproportionally 
increased) is a beneficial physiological effect. In weighing the evidence, the Panel took into account that in the 
human intervention studies, from which conclusions could be drawn, FRUIT UP
®
 decreased post-prandial blood 
glucose responses compared with glucose but not compared with sucrose, and that this effect may be explained 
by the partial replacement of glucose by fructose. The Panel concludes that a cause and effect relationship has not 
been established between the consumption of FRUIT UP
®
 and a reduction of post-prandial glycaemic responses 
over and above the well-established effect of fructose on reducing post-prandial glycaemic responses when 
replacing glucose in foods. 




, post-prandial blood glucose responses, health claims 
                                                     
1 On request from the Competent Authority of Spain following an application by WILD-Valencia SAU, Question No EFSA-
Q-2014-00405, adopted on 22 April 2015. 
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SUMMARY 
Following an application from WILD-Valencia SAU, submitted for authorisation of a health claim 
pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Spain, the 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on 
the scientific substantiation of a health claim related to FRUIT UP
®
 and a reduction of post-prandial 
blood glucose responses. 
The scope of the application was proposed to fall under a health claim based on newly developed 
scientific evidence. The application included a request for the protection of proprietary data. 
The food that is the subject of the health claim is FRUIT UP
®
, a water extract from carob pods 
(Ceratonia siliqua L.) which, according to the applicant, should replace “high glycaemic 
carbohydrates” in foods or beverages in order to obtain the claimed effect (i.e. a reduction of post-
prandial glycaemic responses). The Panel considers that the term “high-glycaemic carbohydrates” is 
not sufficiently defined. In the human intervention studies which were provided by the applicant in 
the original application, glucose and sucrose were used as the reference foods. The Panel considers 
that glucose and sucrose are the comparator foods. The Panel considers that the food, FRUIT UP
®
, 
which is the subject of the health claim, and the food (i.e. glucose, sucrose) which FRUIT UP
®
 should 
replace in foods or beverages, are sufficiently characterised in relation to the claimed effect. 
The claimed effect proposed by the applicant is the “reduction of post-prandial blood glucose 
responses”. The target population proposed by the applicant is: “individuals from the general 
population wishing to reduce their post-prandial glycaemic responses”. The Panel considers that a 
reduction of post-prandial glycaemic responses (as long as post-prandial insulinaemic responses are 
not disproportionally increased) is a beneficial physiological effect. 
The applicant submitted one published and 16 unpublished human intervention studies as being 
pertinent to the health claim. 
One study assessed the effect of chronic consumption of FRUIT UP
®
 on a long-term reduction in 
post-prandial blood glucose responses. Upon a request for clarification of the claimed effect and for 
further information on the study, the applicant provided clarification of the claimed effect and 
indicated that the study was no longer pertinent to the claim. At that time, the applicant also submitted 
one additional study which did not provide an analysis of post-prandial glycaemic responses. The 
Panel considers that no conclusions can be drawn from these studies for the scientific substantiation 
of the claim. 
The remaining 15 human studies assessed post-prandial blood glucose responses after the 
consumption of FRUIT UP
®
 or FRUIT UP
®
-based drinks as compared with glucose (14 studies) or 
compared with sucrose (one study). In two of these studies, post-prandial insulinaemic responses were 
also assessed. 
Compared with glucose, the consumption of FRUIT UP
®
 and FRUIT UP
®
-based drinks significantly 
decreased post-prandial blood glucose responses. This effect was not observed when FRUIT UP
®
 was 
compared with sucrose. 
Post-prandial insulinaemic responses were shown not to be increased following consumption of 
FRUIT UP
®
 compared with the reference foods, i.e. glucose and sucrose, respectively. 
The Panel considers that the significantly lower post-prandial glycaemic responses observed with the 
consumption of FRUIT UP
®
 and FRUIT UP
®
-based beverages, compared with pure glucose, could be 
explained by the partial replacement of glucose with fructose in FRUIT UP
®
. The Panel also notes 
that the only study which compared FRUIT UP
®
 with similar amounts of sugars from sucrose 
FRUIT UP
®
 and a reduction of post-prandial blood glucose responses 
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(contains a similar proportion of glucose and fructose as found in FRUIT UP
®
) did not show a 
significant effect of FRUIT UP
®
 on post-prandial glycaemic responses (i.e. as compared with 
sucrose). 
The Panel also notes that none of the studies which compared FRUIT UP
®
 with glucose provides 
information on an independent effect of the so-claimed “bio-active” substances in FRUIT UP® on the 
reduction of post-prandial blood glucose responses (i.e. on an effect of FRUIT UP
®
 over and above 
the effect which could be expected from the partial replacement of glucose with fructose). 
In weighing the evidence, the Panel took into account that in the human intervention studies, from 
which conclusions could be drawn, FRUIT UP
®
 decreased post-prandial blood glucose responses 
compared with glucose but not compared with sucrose, and that this effect may be explained by the 
partial replacement of glucose with fructose. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of FRUIT UP
®
 and a reduction of post-prandial glycaemic responses over and above the 
well-established effect of fructose on reducing post-prandial glycaemic responses when replacing 
glucose in foods. 
FRUIT UP
®
 and a reduction of post-prandial blood glucose responses 
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of 
this Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this 
Regulation lays down provisions for the addition of claims (other than those referring to the reduction 
of disease risk and to children’s development and health) which are based on newly developed 
scientific evidence, or which include a request for the protection of proprietary data, to the 
Community list of permitted claims referred to in Article 13(3). 
According to Article 18 of this Regulation, an application for inclusion in the Community list of 
permitted claims referred to in Article 13(3) shall be submitted by the applicant to the national 
competent authority of a Member State, which will make the application and any supplementary 
information supplied by the applicant available to the European Food Safety Authority (EFSA). 
STEPS TAKEN BY EFSA 
 The application was received on 10/06/2014. 
 The scope of the application was proposed to fall under a health claim based on newly 
developed scientific evidence. The application included a request for the protection of 
proprietary data. 
 On 31/07/2014, during the validation process of the application, EFSA sent a request to the 
applicant to provide missing information. 
 On 16/09/2014, EFSA received the missing information as submitted by the applicant. 
 The scientific evaluation procedure started on 29/09/2014. 
 On 27/11/2014, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application, and the 
scientific evaluation was suspended on 10/12/2014, in compliance with Article 18(3) of 
Regulation (EC) No 1924/2006. 
 On 19/12/2014, EFSA received the applicant’s reply and the scientific evaluation was 
restarted, in compliance with Article 18(3) of Regulation (EC) No 1924/2006. 
 On 22/01/2015, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application, and the 
scientific evaluation was suspended on 29/01/2015, in compliance with Article 18(3) of 
Regulation (EC) No 1924/2006. 
 On 11/02/2015, EFSA received the applicant’s reply and the scientific evaluation was 
restarted, in compliance with Article 18(3) of Regulation (EC) No 1924/2006. 
 During its meeting on 22/04/2015, the NDA Panel, having evaluated the data submitted, 
adopted an opinion on the scientific substantiation of a health claim related to FRUIT UP
®
 
and a reduction of post-prandial blood glucose responses. 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
FRUIT UP
®
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TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with 
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the scientific substantiation of a health claim related to: FRUIT UP
®
 and a reduction of 
post-prandial blood glucose responses. 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the 
marketing of FRUIT UP
®
, a positive assessment of its safety, nor a decision on whether FRUIT UP
®
 
is, or is not, classified as a foodstuff. It should be noted that such an assessment is not foreseen in the 
framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. 
FRUIT UP
®
 and a reduction of post-prandial blood glucose responses 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address 
WILD-Valencia SAU, Partida La Coma s/n, E-46740 Carcaixent, Spain. 
The application includes a request for the protection of proprietary data, in accordance with Article 21 
of Regulation (EC) No 1924/2006. 
Food/constituent as stated by the applicant 
According to the applicant, the food that is the subject of the health claim is FRUIT UP
®
, which is a 
carbohydrate extract from carob pods (Ceratonia siliqua L.). 
Health relationship as claimed by the applicant 
According to the applicant, consumption of FRUIT UP
®
 leads to a reduction in post-prandial blood 
glucose responses. 
With regard to the proposed mechanism of action, the applicant claims that FRUIT UP
®
 may exert its 
effect on post-prandial blood glucose responses because of its content of various “bio-active” 
substances, e.g. pinitol (6.77 ± 0.22 g/100 g), myo-inositol (0.72 ± 0.04 g/100 g), arabinoxylan 
(2.21 ± 0.34 g/100 g) and kestose (0.34 ± 0.11 g/100 g). In particular, pinitol and myo-inositol may, 
according to the applicant, improve insulin sensitivity (e.g. by inducing the translocation of glucose 
transporter type (GLUT) 4 within skeletal muscle cells), and may also improve markers of oxidative 
stress and inflammation. In addition, the applicant claims an inhibition of glucose absorption in the 
small intestine, partly because of the fibres (i.e. arabinoxylan and kestose) present in FRUIT UP
®
, but 
also because of a decrease in intestinal GLUT2 translocation. 
Wording of the health claim as proposed by the applicant 
In the original application, the applicant has proposed the following wording for the health claim: 
“FRUIT UP® induces a lower blood glucose rise than high glycaemic carbohydrates”. Following a 
request for clarification of the claimed effect, the applicant proposed the following wording for the 
health claim: “FRUIT UP® reduces post-prandial blood glucose responses compared to high-
glycaemic carbohydrates”. 
Specific conditions of use as proposed by the applicant 
In the original application, the applicant proposed, as conditions of use for the health claim, a daily 
consumption of 60–70 g FRUIT UP® in two intakes (i.e. 30–35 g of FRUIT UP® twice daily). 
Following a request for clarification of the claimed effect, the applicant proposed the following 
conditions of use for the health claim: “High glycaemic carbohydrates should be replaced in foods or 
drinks by FRUIT UP
®
 so that foods or drinks contain reduced amounts of sugars as per Annex of 
Regulation (EC) No 1924/2006. This regulation indicates that the reduction in high glycaemic 
carbohydrates should be at least 30 %”. 
The target population proposed by the applicant is individuals from the general population wishing to 
reduce their post-prandial glycaemic responses. 
FRUIT UP
®
 and a reduction of post-prandial blood glucose responses 
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ASSESSMENT 
1. Characterisation of the food/constituent 
The food that is the subject of the health claim is FRUIT UP
®
, a water extract from carob pods 
(Ceratonia siliqua L.), which, according to the applicant, should replace “high glycaemic 
carbohydrates” in foods or beverages in order to obtain the claimed effect (i.e. a reduction of post-
prandial glycaemic responses). 
FRUIT UP
®
 is extracted from the seedless fruits (i.e. pods) of the carob tree (Ceratonia siliqua L.) by 
water extraction, followed by blending with apple juice and white grape juice from concentrate. The 
mix of fruit juices is then further processed and concentrated to give a sugar content of 70 ± 1°Bx. 
Carob fruit (95.5–99.5 %) is the major source of soluble carbohydrates in FRUIT UP®. Detailed 
information on its composition was provided (as average ± SD per 100 g of FRUIT UP
®
), as follows: 
34.8 ± 2.6 g sucrose, 11.0 ± 1.3 g glucose, 9.5 ± 1.0 g fructose, fibres (e.g. 2.2 ± 0.3 g arabinoxylan 
and 0.3 ± 0.1 g kestose) and polyols (e.g. 6.8 ± 0.2 g pinitol and 0.7 ± 0.04 g myo-inositol). 
An overview of the manufacturing process, and batch-to-batch variability and stability data were 
provided. 
Following a request for a definition of “high-glycaemic carbohydrates”, which was proposed by the 
applicant as the reference food which ought to be replaced by FRUIT UP
®
 in order to obtain the 
claimed effect, the applicant indicated that “high-glycaemic carbohydrates” refers to “any 
carbohydrate rapidly digested and absorbed in the small intestine that induces a high increase in 
plasma glucose level, as for example glucose, maltose, glucose syrup, maltodextrin, high digestible 
starches, and sucrose”. In response to a further request for clarification of “high digestible starches” 
and the meaning of “high increase”, the applicant indicated that “high digestible starches” correspond 
to “rapid digestible starches which are known to induce a rapid elevation of blood glucose”, and that 
the term “high increase” means an “increase in blood glucose corresponding to at least 70 % of the 
glucose response”. 
The Panel considers that the term “high-glycaemic carbohydrates” is not sufficiently defined. The 
Panel notes that in the human intervention studies, which were provided by the applicant in the 
original application, glucose and sucrose were used as the reference foods. The Panel considers that 
glucose and sucrose are the comparator foods which ought to be replaced by FRUIT UP
®
 in order to 
obtain the claimed effect. 
The Panel considers that the food, FRUIT UP
®
, which is the subject of the health claim, and the food 
(i.e. glucose, sucrose) which FRUIT UP
®
 should replace in foods or beverages, are sufficiently 
characterised in relation to the claimed effect. 
2. Relevance of the claimed effect to human health 
The claimed effect proposed by the applicant is the “reduction of post-prandial blood glucose 
responses”. The target population proposed by the applicant is: “individuals from the general 
population wishing to reduce their post-prandial glycaemic responses”. 
The conditions of use (i.e. “daily consumption of 60–70 g FRUIT UP® in two intakes”), as submitted 
in the original application, suggested a claim on long-term reduction of post-prandial blood glucose 
responses following consumption of carbohydrate-rich meals when FRUIT UP
®
 is consumed for 
extended periods of time on a regular basis. Following a request for clarification of the claimed effect, 
the applicant indicated the wish to apply for a claim on the reduction of post-prandial blood glucose 
responses following the consumption of FRUIT UP
®
 compared with a reference food, rather than 
long-term reduction of post-prandial blood glucose responses. 
FRUIT UP
®
 and a reduction of post-prandial blood glucose responses 
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The elevation of blood glucose concentrations after the consumption of a food and/or a meal, i.e. post-
prandial glycaemia, is a normal physiological response which varies in magnitude and duration, and 
which may be influenced by the chemical and physical nature of the food or meal consumed, as well 
as by individual factors (Venn and Green, 2007). Decreasing post-prandial glycaemic responses may, 
for example, be beneficial to individuals with impaired glucose tolerance, as long as post-prandial 
insulinaemic responses are not disproportionally increased. Impaired glucose tolerance is common in 
the general adult population. 
The Panel considers that a reduction of post-prandial glycaemic responses (as long as post-prandial 
insulinaemic responses are not disproportionally increased) is a beneficial physiological effect. 
3. Scientific substantiation of the claimed effect 
The applicant performed a literature search in PubMed using the search term “pinitol” and setting a 
filter for “human”. In addition, the company’s archives were searched for pertinent studies. Studies 
were considered pertinent if they assessed the effect of FRUIT UP
®
 on post-prandial glycaemia in 
healthy humans and were published in English or French. Studies conducted with “pinitol sources 
different from FRUIT UP
®” and studies which were carried out in patients with type 2 diabetes (or 
any other disease which might have had an influence on blood glucose concentrations) were excluded. 
The applicant submitted one published and 16 unpublished human intervention studies as being 
pertinent to the health claim. 
One study (Bañuls et al., 2014, unpublished, claimed as proprietary by the applicant) assessed the 
effect of chronic consumption (i.e. twice a day for three months) of FRUIT UP
®
 compared with a 
sucrose drink on a long-term reduction of post-prandial blood glucose responses. Upon a request for 
clarification of the claimed effect and for further information on the study, the applicant indicated the 
wish to apply for a claim on the reduction of post-prandial blood glucose responses following the 
consumption of FRUIT UP
®
 compared with a reference food, rather than the long-term reduction of 
post-prandial blood glucose responses and that, therefore, this study was no longer pertinent. At that 
time, the applicant also submitted one additional study (Henry et al., 2007c, unpublished, claimed as 
proprietary by the applicant), which, according to the applicant, “has been conducted with high 
amounts of FRUIT UP
®
 (171 g, corresponding to 120 g dry matter, and providing 12 g of pinitol) and 
had been excluded from the initial application due to this reason”. In the study, seven subjects 
consumed either FRUIT UP
®
 (171 g, providing 13.2 g glucose, 11.4 g fructose, 41.8 g sucrose and 
12 g pinitol) or a deionised apple juice (14.5 g glucose, 28.6 g fructose and 6.6 g sucrose) three times 
per day. Interstitial glucose was measured every five minutes over 24 hours by means of a continuous 
glucose monitoring system. No analysis was provided on post-prandial blood glucose responses. The 
Panel notes that no analysis of post-prandial glycaemic responses was provided. The Panel considers 
that no conclusions can be drawn from these studies for the scientific substantiation of the claim. 
The remaining 15 human studies (all randomised, controlled cross-over trials) assessed post-prandial 
blood glucose responses after the consumption of FRUIT UP
®
 or FRUIT UP
®
-based drinks compared 
with glucose (14 studies) or compared with sucrose (one study). In two of these studies, post-prandial 
insulinaemic responses were also assessed. 
Compared with glucose, the consumption of FRUIT UP
®
 (Henry et al., 2005, 2007a, b, 2008a, b; 
Sydney University, 2008) and FRUIT UP
®
-based drinks (Henry et al., 2008c, d, e, 2009a, b, 2010a, b; 
Thondre and Lightowler, 2012) significantly decreased post-prandial blood glucose responses. This 
effect was not observed when FRUIT UP
®
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Post-prandial insulinaemic responses were shown not to be increased following consumption of 
FRUIT UP
®
 compared with the reference foods, i.e. glucose and sucrose, respectively (Henry et al., 
2009b; Hernández-Mijares et al., 2013). 
The Panel notes that post-prandial glycaemic responses following consumption of fructose are about 
20 % lower than the post-prandial glycaemic responses following consumption of the same amounts 
of glucose. Considering that sucrose is a disaccharide of glucose and fructose, the significantly lower 
post-prandial glycaemic responses observed with the consumption of FRUIT UP
®
 and FRUIT UP
®
-
based beverages, compared with pure glucose, could be explained by the partial replacement of 
glucose with fructose in FRUIT UP
®
. The Panel also notes that the only study which compared 
FRUIT UP
®
 with similar amounts of sugars from sucrose (contains a similar proportion of glucose 
and fructose as found in FRUIT UP
®
) did not show a significant effect of FRUIT UP
®
 on post-
prandial glycaemic responses (compared with sucrose). Therefore, the applicant was informed by 
EFSA that a claim on fructose as compared with glucose or sucrose and a reduction of post-prandial 
blood glucose responses had already been evaluated with a favourable outcome (EFSA NDA Panel, 
2011). 
In reply, the applicant claimed that the effect of FRUIT UP
®
 on post-prandial blood glucose responses 
observed in the studies using glucose as the comparator could not only be explained by a partial 
replacement of glucose with fructose, but were also likely to be caused by the presence of various 
“bio-active” substances, in particular pinitol and myo-inositol, in FRUIT UP®. The applicant also 
claimed that FRUIT UP
®
 decreased post-prandial blood glucose responses compared with sucrose in 
the only study (Hernández-Mijares et al., 2013) available. The Panel notes that the only study 
available comparing FRUIT UP
®
 with sucrose did not find significant differences in the post-prandial 
blood glucose responses. The Panel also notes that none of the studies which compared FRUIT UP
®
 
with glucose provides information on an independent effect of the so-claimed “bio-active” substances 
in FRUIT UP
®
 on the reduction of post-prandial blood glucose responses (i.e. on an effect of 
FRUIT UP
®
 over and above the effect which could be expected from the partial replacement of 
glucose with fructose). 
The Panel notes that, in the absence of evidence for an effect of FRUIT UP
®
 on a reduction of post-
prandial blood glucose responses beyond which could be expected by the partial replacement of 
glucose with fructose in humans, animal studies on other potential mechanisms were not considered 
by the Panel for the scientific substantiation of the claim. 
In weighing the evidence, the Panel took into account that in the human intervention studies, from 
which conclusions could be drawn, FRUIT UP
®
 decreased post-prandial blood glucose responses 
compared with glucose but not compared with sucrose, and that this effect may be explained by the 
partial replacement of glucose with fructose. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of FRUIT UP
®
 and a reduction of post-prandial glycaemic responses over and above the 
well-established effect of fructose on reducing post-prandial glycaemic responses when replacing 
glucose in foods. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food, FRUIT UP®, which is the subject of the health claim, and the food (i.e. glucose, 
sucrose) which FRUIT UP
®
 should replace in foods or beverages, are sufficiently 
characterised in relation to the claimed effect. 
FRUIT UP
®
 and a reduction of post-prandial blood glucose responses 
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 The claimed effect proposed by the applicant is the “reduction of post-prandial blood glucose 
responses”. The target population proposed by the applicant is: “individuals from the general 
population wishing to reduce their post-prandial glycaemic responses”. A reduction of post-
prandial glycaemic responses (as long as post-prandial insulinaemic responses are not 
disproportionally increased) is a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of 
FRUIT UP
®
 and a reduction of post-prandial glycaemic responses over and above the well-
established effect of fructose on reducing post-prandial glycaemic responses when replacing 
glucose in foods. 
DOCUMENTATION PROVIDED TO EFSA 
1. Health claim application on FRUIT UP® and reduction of post-prandial blood glucose responses 
pursuant to Article 13(5) of Regulation (EC) No 1924/2006 (EFSA-Q-2014-00405, Claim serial 
No: 0418_ES). June 2014. Submitted by WILD-Valencia SAU. 
REFERENCES 
Bañuls C, Rocha M, Rovira-Llopis S, Falcón R, Veses S, Monzó N, Victor VM and 
Hernández‐Mijares A, 2014 (unpublished, claimed as proprietary by the applicant). Chronic 
consumption of pinitol-enriched carob fruit extract improves insulin sensitivity and postprandial 
glycaemia in healthy subjects. 
EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition, and Allergies), 2010. Scientific 
Opinion on Dietary Reference Values for carbohydrates and dietary fibre. EFSA Journal 
2010;8(3):1462, 77 pp. doi:10.2903/j.efsa.2010.1462 
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